Compare Las Vegas Sands Corp. (LVS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Las Vegas Sands Corp. trades at $36.77 (market cap $23.98B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Las Vegas Sands Corp. is far larger — about 3.3× Spyre Therapeutics Inc. Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 73 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LVS | SYRE | |
|---|---|---|
Market Cap | $23.98B | $7.35B |
Volume | 5,962,073 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $108.92 |
52-Week Low | $35.81 | $22.18 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $35.86B | $6.35B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $37.04, up 2.46% today, amid a bearish technical signal. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $58.89 price target, indicating significant upside potential. Recent news highlights Sands China's community initiatives and operational milestones, reinforcing its market presence.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and market volatility. Investment opportunity lies in the valuation discount relative to growth prospects, though investors should monitor earnings consistency and macroeconomic factors affecting the gaming and hospitality sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
